Lilly, Astellas circle Sangamo assets as biotech files for bankruptcy - BioSpace
Sangamo Therapeutics will lay off 51 members of its workforce while retaining 77 people to continue work on the programs central to Astellas and Eli Lilly's bids.
Ähnliche Seiten
Gene Editing Pioneer Sangamo Files for Chapter 11 Bankruptcy; Agrees to Sell Assets